Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study

• Published in: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Vol. 19; no. 1; pp. 114 - 121
• Main Authors: Roberts, K.J., Bannister, C.A., Schrem, H.
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01.01.2019; Elsevier Limited
• Subjects: Adenocarcinoma; Age; Aged; Blood pressure; Cancer therapies; Chemotherapy; Enzyme Replacement Therapy; Enzymes; Exocrine Pancreatic Insufficiency - drug therapy; Exocrine Pancreatic Insufficiency - etiology; Family medical history; Female; Humans; Male; Malnutrition; Middle Aged; Mortality; Observational Studies as Topic; Pancreatic cancer; Pancreatic enzyme replacement therapy; Pancreatic exocrine insufficiency; Pancreatic Neoplasms; Pancreatic Neoplasms - complications; Pancreatic Neoplasms - therapy; Pancrelipase - therapeutic use; Patients; Population; Population studies; Population-based studies; Retrospective Studies; Studies; Surgery; Survival; Survival Analysis; United Kingdom > UK; England; Pancreatic enzyme replacement therapy; Pancreatic cancer; Pancreatic exocrine insufficiency

Pancreatic exocrine insufficiency (PEI) and malnutrition are prevalent among patients with pancreatic adenocarcinoma. Pancreatic enzyme replacement therapy (PERT) can correct PEI but its use among patients with pancreatic cancer is unclear as are effects upon survival. This population-based study so...